bioAffinity Technologies Inc. has announced that the China National Intellectual Property Administration has issued a notification of patent grant for the company's novel method and composition aimed at selectively killing cancer cells. The newly granted Chinese patent, titled "Compositions and Methods for Treating Cancer," protects bioAffinity's innovative RNA-based therapeutic strategy, which focuses on targeting the CD320 and LRP2 receptors on cancer cell membranes. This patent enhances global protection for the company's siRNA-based therapies, which have demonstrated effectiveness in causing cancer cell death without affecting normal cells. The technology is being explored for topical treatment applications, particularly for skin cancers.